NovaBridge Biosciences Files 6-K, Incorporates Exhibits

Ticker: NBP · Form: 6-K · Filed: Oct 31, 2025 · CIK: 1778016

Sentiment: neutral

Topics: sec-filing, regulatory-update, registration-statement

TL;DR

NovaBridge filed a 6-K, incorporating Exhibit 99.1 into its F-3 and S-8 filings. Standard regulatory update.

AI Summary

NovaBridge Biosciences filed a Form 6-K on October 31, 2025, reporting for the month of October 2025. The filing indicates that Exhibit 99.1 is incorporated by reference into several of the company's Registration Statements on Form F-3 and Form S-8. The company's principal executive offices are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.

Why It Matters

This filing is a routine report that incorporates previous information into ongoing registration statements, which is important for regulatory compliance and investor information regarding the company's securities.

Risk Assessment

Risk Level: low — This is a routine SEC filing (Form 6-K) that primarily incorporates existing documents by reference, indicating no new material events or significant financial changes.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC that the issuer makes or is required to make public in its home country.

What does it mean for Exhibit 99.1 to be 'incorporated by reference'?

Incorporation by reference means that the content of Exhibit 99.1 is legally considered part of the specified Registration Statements (Form F-3 and Form S-8) as if it were physically included within them.

What are the company's principal executive offices?

The company's principal executive offices are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.

What is the filing date and period of report for this 6-K?

The filing date is October 31, 2025, and the conformed period of report is also October 31, 2025.

Which specific registration statements are mentioned in the filing?

The filing mentions Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File Nos. 333-239871, 333-256603, 333-265684, 333-279842, and 333-290195).

Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2025-10-31 06:04:41

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NovaBridge Biosciences By : /s/ Xi-Yong Fu Name : Xi-Yong (Sean) Fu Title : Chief Executive Officer Date: October 31, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing